Adar1 Capital Management buys $1.6m in NextCure (NXTC) shares By Investing.com

ADAR1 Capital Management, LLC, a 10% owner and director of NextCure, Inc. (), acquired common stock totaling $1,624,120 through multiple transactions on July 30 and July 31, 2026.

The investment firm purchased a total of 329,153 shares of NextCure common stock. The prices paid for these shares ranged from $4.80 to $5.00 per share. Following these transactions, ADAR1 Capital Management, LLC indirectly holds 722,419 shares of NextCure common stock.The insider buying comes as NextCure stock trades at $4.40, down nearly 19% over the past week. According to InvestingPro analysis, the stock appears undervalued relative to its Fair Value estimate, with the company holding more cash than debt on its balance sheet. InvestingPro offers 10 additional exclusive tips for NXTC subscribers.

According to footnotes in the filing, the reported securities are directly owned by private investment funds managed by ADAR1 Capital Management, LLC. These shares may be deemed indirectly beneficially owned by ADAR1 Capital Management, LLC and Daniel Schneeberger, its sole manager. The reporting persons disclaim beneficial ownership of these securities except to the extent of their pecuniary interest.

The Form 4 filing detailing these transactions was signed by Daniel Schneeberger, Manager of ADAR1 Capital Management, LLC, on August 3, 2026.

In other recent news, NextCure Inc. has announced a merger agreement with Avere Therapeutics, Inc., valued at $320 million. This all-stock transaction includes a significant private placement led by Fairmount and Hansoh Pharmaceutical Group Co., Ltd., and is expected to be completed in the second half of 2026. Following the merger, the combined entity will operate under the name Avere Therapeutics, Inc. and trade on Nasdaq. Meanwhile, NextCure reported a 55% response rate for its investigational drug SIM0505 in gynecologic cancers, as presented at the American Society for Clinical Oncology conference. The company has also initiated a dose optimization study for SIM0505 targeting platinum-resistant ovarian cancer, aiming to finalize dose selection for future studies.

In terms of analyst activity, H.C. Wainwright reiterated a Buy rating on NextCure, maintaining a price target of $20.00, following the merger news. Lucid Capital Markets initiated coverage on NextCure with a Buy rating and a $25.00 price target, highlighting the company’s antibody-drug conjugate pipeline. The firm emphasized SIM0505 as a central focus due to its engineered properties for improved therapeutic outcomes. These developments reflect significant progress in NextCure’s strategic and clinical initiatives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.